share_log

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

《每日生物技術脈搏》:羅氏的肺癌組合療法未能通過後期研究,Adagio 在 COVID 抗體陽性數據上飆升,Amylyx 正在等待 Adcom 的判決
Benzinga Real-time News ·  2022/03/30 08:04
Here's a roundup of top developments in the biotech space over the last 24 hours.
以下是過去24小時生物技術領域的最新進展綜述。
Stocks In Focus
關注的股票
J&J, ViiV Co-developed Long-Acting HIV Treatment Gets FDA Approval For Treating Adolescents
強生,歡躍聯合開發的長效HIV療法獲得FDA批准用於治療青少年
Johnson & Johnson's (NYSE:JNJ) Janssen unit said the U.S. Food and Drug Administration has approved Cabenuva (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents, who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.
強生(紐約證券交易所股票代碼:JNJ)Janssen子公司表示,美國食品和藥物管理局已經批准Cabenuva(卡波替格列韋和利培韋林)用於治療病毒抑制青少年的HIV-1,這些青少年年齡在12歲或以上,體重至少35公斤,正在接受穩定的抗逆轉錄病毒治療,沒有治療失敗的歷史,也沒有已知或懷疑對卡波替格列韋或利培韋林產生耐藥性。
Cabenuva...
C...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論